[AEONCR] QoQ Cumulative Quarter Result on 30-Nov-2018 [#3]

Stock
[AEONCR] AEON CREDIT SERVICE (M) BHD
Announcement Date
20-Dec-2018
Admission Sponsor
-
Sponsor
-
Financial Year
28-Feb-2019
Quarter
30-Nov-2018 [#3]
Profit Trend
QoQ- 48.44%
YoY- 22.62%
Quarter Report
Latest QR
Upcoming QR
AEONCR's Result
AEONCR's Financial Summary
View:
Show?
Cumulative Result
31/08/19 31/05/19 28/02/19 30/11/18 31/08/18 31/05/18 28/02/18 CAGR
Revenue 783,034 378,588 1,365,843 1,006,307 657,810 325,718 1,235,122 -26.14%
PBT 179,544 112,668 472,191 357,068 238,996 131,763 398,335 -41.12%
Tax -45,817 -28,068 -117,567 -90,057 -59,121 -32,528 -98,278 -39.79%
NP 133,727 84,600 354,624 267,011 179,875 99,235 300,057 -41.56%
-
NP to SH 133,727 84,600 354,624 267,011 179,875 99,235 300,057 -41.56%
-
Tax Rate 25.52% 24.91% 24.90% 25.22% 24.74% 24.69% 24.67% -
Total Cost 649,307 293,988 1,011,219 739,296 477,935 226,483 935,065 -21.53%
-
Net Worth 1,549,719 1,593,121 1,526,741 1,417,541 1,392,929 1,356,183 1,580,632 -1.30%
Dividend
31/08/19 31/05/19 28/02/19 30/11/18 31/08/18 31/05/18 28/02/18 CAGR
Div 56,806 - 113,867 55,724 55,542 - 102,058 -32.26%
Div Payout % 42.48% - 32.11% 20.87% 30.88% - 34.01% -
Equity
31/08/19 31/05/19 28/02/19 30/11/18 31/08/18 31/05/18 28/02/18 CAGR
Net Worth 1,549,719 1,593,121 1,526,741 1,417,541 1,392,929 1,356,183 1,580,632 -1.30%
NOSH 250,893 250,868 250,802 250,733 249,735 249,199 248,449 0.65%
Ratio Analysis
31/08/19 31/05/19 28/02/19 30/11/18 31/08/18 31/05/18 28/02/18 CAGR
NP Margin 17.08% 22.35% 25.96% 26.53% 27.34% 30.47% 24.29% -
ROE 8.63% 5.31% 23.23% 18.84% 12.91% 7.32% 18.98% -
Per Share
31/08/19 31/05/19 28/02/19 30/11/18 31/08/18 31/05/18 28/02/18 CAGR
RPS 306.70 148.29 534.98 401.80 263.52 130.89 497.76 -27.52%
EPS 48.73 32.69 133.55 102.80 69.45 38.43 143.01 -51.11%
DPS 22.25 0.00 44.60 22.25 22.25 0.00 41.13 -33.53%
NAPS 6.07 6.24 5.98 5.66 5.58 5.45 6.37 -3.15%
Adjusted Per Share Value based on latest NOSH - 250,733
31/08/19 31/05/19 28/02/19 30/11/18 31/08/18 31/05/18 28/02/18 CAGR
RPS 153.40 74.16 267.57 197.13 128.86 63.81 241.96 -26.13%
EPS 26.20 16.57 69.47 52.31 35.24 19.44 58.78 -41.56%
DPS 11.13 0.00 22.31 10.92 10.88 0.00 19.99 -32.24%
NAPS 3.0359 3.1209 2.9909 2.7769 2.7287 2.6567 3.0964 -1.30%
Price Multiplier on Financial Quarter End Date
31/08/19 31/05/19 28/02/19 30/11/18 31/08/18 31/05/18 28/02/18 CAGR
Date 30/08/19 31/05/19 28/02/19 30/11/18 30/08/18 31/05/18 28/02/18 -
Price 15.00 16.10 16.54 15.20 15.10 14.80 13.30 -
P/RPS 4.89 10.86 3.09 3.78 5.73 11.31 2.67 49.52%
P/EPS 28.64 48.59 11.91 14.26 20.96 37.11 11.00 88.92%
EY 3.49 2.06 8.40 7.01 4.77 2.69 9.09 -47.08%
DY 1.48 0.00 2.70 1.46 1.47 0.00 3.09 -38.70%
P/NAPS 2.47 2.58 2.77 2.69 2.71 2.72 2.09 11.74%
Price Multiplier on Announcement Date
31/08/19 31/05/19 28/02/19 30/11/18 31/08/18 31/05/18 28/02/18 CAGR
Date 26/09/19 27/06/19 25/04/19 20/12/18 04/10/18 28/06/18 27/04/18 -
Price 14.96 16.92 16.78 14.84 15.86 13.90 12.82 -
P/RPS 4.88 11.41 3.14 3.69 6.02 10.62 2.58 52.76%
P/EPS 28.56 51.06 12.08 13.92 22.01 34.86 10.60 93.27%
EY 3.50 1.96 8.28 7.18 4.54 2.87 9.43 -48.26%
DY 1.49 0.00 2.66 1.50 1.40 0.00 3.21 -39.96%
P/NAPS 2.46 2.71 2.81 2.62 2.84 2.55 2.01 14.37%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment